Respiratory Syncytial Virus Vaccination Recommendations and Other Updates From ACIP

• 2023

  Log in to bookmark this resource.

  Log in
• Pamela Rockwell
PMID: 37843960

---

Access Resources

• Journal ArticleEN
• Ask aRCie About This Resource

About

This 2-page practice guideline highlights the impact of respiratory syncytial virus (RSV) infection in the United States, causing severe respiratory illness, especially in infants and older adults. RSV is a common cause of childhood illness, leading to hospitalizations and deaths annually. It discusses the seasonal nature of RSV epidemics, which have been affected by the COVID-19 pandemic. These recommendations aim to reduce illness caused by RSV and improve public health safety.

---

Tags

Focus Area: Infectious Disease

Audience: Physicians

Emergency Management Stages: Response; Preparedness (Prevention / Protection)

Bundles: Nirsevimab Library

Keywords: Antiviral Agents; Immunization Schedule; Infant; Respiratory Syncytial Virus Infections; Respiratory Syncytial Viruses; Vaccination; Practice Guideline

Institutions: University of Michigan

---

More like this

Cost-Effectiveness of Nirsevimab for Respiratory Syncytial Virus in Infants and Young Children 2024 · University of Michigan, Centers for Disease Control and Prevention (CDC), U.S. Public Health Service Cost-Effectiveness of Maternal Vaccination to Prevent Respiratory Syncytial Virus Illness 2024 · University of Michigan, Centers for Disease Control and Prevention (CDC), U.S. Public Health Service Therapies to Decrease Severe Respiratory Syncytial Virus Illness 2024 · U.S. Department of Veterans Affairs, University of Michigan, JAMA

---

The information provided on this website is for educational purposes only. It does not substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

---